$SYRE
Spyre Therapeutics, Inc.

2018 Q3 Form 10-Q Financial Statement

#000156459018028293 Filed on November 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q3
Revenue $0.00 $1.261M
YoY Change -100.0% 9.75%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.310M $3.020M
YoY Change 9.6% 45.89%
% of Gross Profit
Research & Development $8.930M $6.239M
YoY Change 43.13% 15.75%
% of Gross Profit
Depreciation & Amortization $70.00K $70.00K
YoY Change 0.0% 75.0%
% of Gross Profit
Operating Expenses $12.24M $6.239M
YoY Change 96.19% -16.26%
Operating Profit -$12.24M -$7.998M
YoY Change 53.08% 26.93%
Interest Expense $340.0K $140.0K
YoY Change 142.86% 100.0%
% of Operating Profit
Other Income/Expense, Net $326.0K $124.0K
YoY Change 162.9% -1340.0%
Pretax Income -$11.92M -$7.870M
YoY Change 51.46% 26.12%
Income Tax
% Of Pretax Income
Net Earnings -$11.92M -$7.874M
YoY Change 51.35% 26.23%
Net Earnings / Revenue -624.43%
Basic Earnings Per Share
Diluted Earnings Per Share -$542.1K -$479.6K
COMMON SHARES
Basic Shares Outstanding 16.45M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $64.70M $55.70M
YoY Change 16.16% -18.09%
Cash & Equivalents $14.53M $13.16M
Short-Term Investments $50.20M $42.60M
Other Short-Term Assets $3.200M $1.300M
YoY Change 146.15% -38.1%
Inventory
Prepaid Expenses
Receivables $2.400M $2.500M
Other Receivables $0.00 $0.00
Total Short-Term Assets $70.40M $59.50M
YoY Change 18.32% -17.02%
LONG-TERM ASSETS
Property, Plant & Equipment $800.0K $800.0K
YoY Change 0.0% 166.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $100.0K
YoY Change -100.0%
Total Long-Term Assets $900.0K $1.000M
YoY Change -10.0% 150.0%
TOTAL ASSETS
Total Short-Term Assets $70.40M $59.50M
Total Long-Term Assets $900.0K $1.000M
Total Assets $71.30M $60.50M
YoY Change 17.85% -16.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.100M $600.0K
YoY Change 83.33% 20.0%
Accrued Expenses $6.400M $4.200M
YoY Change 52.38% 35.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.500M $4.900M
YoY Change 53.06% 28.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.0K $100.0K
YoY Change 0.0%
Total Long-Term Liabilities $100.0K $100.0K
YoY Change 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.500M $4.900M
Total Long-Term Liabilities $100.0K $100.0K
Total Liabilities $7.600M $5.000M
YoY Change 52.0% 28.21%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $63.68M $55.50M
YoY Change
Total Liabilities & Shareholders Equity $71.30M $60.50M
YoY Change 17.85% -16.09%

Cashflow Statement

Concept 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$11.92M -$7.874M
YoY Change 51.35% 26.23%
Depreciation, Depletion And Amortization $70.00K $70.00K
YoY Change 0.0% 75.0%
Cash From Operating Activities -$8.500M -$7.370M
YoY Change 15.33% 25.55%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$110.0K
YoY Change -9.09%
Acquisitions
YoY Change
Other Investing Activities $1.500M -$6.180M
YoY Change -124.27% -59.58%
Cash From Investing Activities $1.400M -$6.280M
YoY Change -122.29% -58.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.060M -120.0K
YoY Change -983.33% -250.0%
NET CHANGE
Cash From Operating Activities -8.500M -7.370M
Cash From Investing Activities 1.400M -6.280M
Cash From Financing Activities 1.060M -120.0K
Net Change In Cash -6.040M -13.77M
YoY Change -56.14% -34.71%
FREE CASH FLOW
Cash From Operating Activities -$8.500M -$7.370M
Capital Expenditures -$100.0K -$110.0K
Free Cash Flow -$8.400M -$7.260M
YoY Change 15.7% 23.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19772077
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14641082
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-28000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29381000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000
CY2017Q3 us-gaap Investment Income Net
InvestmentIncomeNet
136000
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1261000
CY2018Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6239000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3314000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3020000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7998000
CY2018Q3 us-gaap Investment Income Net
InvestmentIncomeNet
339000
us-gaap Net Income Loss
NetIncomeLoss
-20753000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.49
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21986989
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
23000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17024000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3723000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3888000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16670188
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16670188
us-gaap Operating Expenses
OperatingExpenses
34046000
us-gaap Operating Expenses
OperatingExpenses
24773000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30158000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
326000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
124000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-11917000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-7874000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16409871
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11894000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7877000
CY2017Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24921000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12243000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21050000
us-gaap Investment Income Net
InvestmentIncomeNet
745000
us-gaap Investment Income Net
InvestmentIncomeNet
332000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-37000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-35000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
708000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
297000
us-gaap Net Income Loss
NetIncomeLoss
-29450000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.42
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
69000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20781000
us-gaap Profit Loss
ProfitLoss
-29450000
us-gaap Profit Loss
ProfitLoss
-20753000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
221000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
183000
agle Payment For Discount Premium On Investments Net
PaymentForDiscountPremiumOnInvestmentsNet
-539000
agle Payment For Discount Premium On Investments Net
PaymentForDiscountPremiumOnInvestmentsNet
-2000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
311000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-82000
us-gaap Share Based Compensation
ShareBasedCompensation
2903000
us-gaap Share Based Compensation
ShareBasedCompensation
1794000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
107000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
15000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
30000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
15000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-656000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1237000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1520000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-275000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
727000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
447000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-20000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-21000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1185000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
486000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24993000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18742000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
219000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
428000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
35500000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
62115000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
22620000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
35170000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13099000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27373000
agle Proceeds From Issuance Of Common Stock Net Of Payments Of Offering Costs
ProceedsFromIssuanceOfCommonStockNetOfPaymentsOfOfferingCosts
37654000
agle Proceeds From Issuance Of Common Stock Net Of Payments Of Offering Costs
ProceedsFromIssuanceOfCommonStockNetOfPaymentsOfOfferingCosts
11380000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2153000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
149000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
39807000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11529000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-34586000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1715000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12817000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47748000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14532000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13162000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
51000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such management estimates include those related to accruals of research and development related costs, stock-based compensation, and certain company income tax related items. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, and marketable securities. The Company&#8217;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies and highly rated banks, subject to certain concentration limits and restrictions on maturities. The Company&#8217;s cash, cash equivalents, and marketable securities are held by financial institutions in the United States that management believes are of high credit quality. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents and bond issuers.</p></div>
CY2018Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
64700000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q3 agle Working Capital
WorkingCapital
62900000
CY2018Q3 agle Number Of Subsidiary Corporations Owned
NumberOfSubsidiaryCorporationsOwned
7
CY2018Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
12800000
CY2018Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
12800000
CY2018Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
50236000
CY2018Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2018Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
35000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
50203000
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
8924000
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
8924000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
37584000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
102000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
37482000
CY2018Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
50203000
CY2017Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
34498000
CY2017Q4 agle Available For Sale Securities Debt Maturities Year One Through Two Fair Value
AvailableForSaleSecuritiesDebtMaturitiesYearOneThroughTwoFairValue
2984000
CY2018Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
50203000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
37482000
CY2018Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1857000
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1837000
CY2018Q3 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
3868000
CY2017Q4 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
2552000
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
625000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
672000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
88000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
159000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2018Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2018Q3 us-gaap Billed Contract Receivables
BilledContractReceivables
2400000
CY2018Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0

Files In Submission

Name View Source Status
0001564590-18-028293-index-headers.html Edgar Link pending
0001564590-18-028293-index.html Edgar Link pending
0001564590-18-028293.txt Edgar Link pending
0001564590-18-028293-xbrl.zip Edgar Link pending
agle-10q_20180930.htm Edgar Link pending
agle-20180930.xml Edgar Link completed
agle-20180930.xsd Edgar Link pending
agle-20180930_cal.xml Edgar Link unprocessable
agle-20180930_def.xml Edgar Link unprocessable
agle-20180930_lab.xml Edgar Link unprocessable
agle-20180930_pre.xml Edgar Link unprocessable
agle-ex102_410.htm Edgar Link pending
agle-ex311_10.htm Edgar Link pending
agle-ex312_8.htm Edgar Link pending
agle-ex321_9.htm Edgar Link pending
agle-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending